Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014;7 Spec No. 2(Spec Iss 2):11-4.

OCT parameters in patients with diabetic maculopathy

R Serban  1 , M Cioboata  1 , C Chiotan  2 , C Cornăcel  1 , R Liora  1 , A Anghelie  1
Affiliations
Randomized Controlled Trial

OCT parameters in patients with diabetic maculopathy

R Serban et al. J Med Life. 2014.

Abstract

The treatment of the clinically significant macular edema in patients with diabetic maculopathy by the intravitreal administration of corticosteroids and antiangiogenic factors requires rapid and more accurate investigation methods aimed at following up the dynamic evolution of the structural parameters of the retina. The purpose of the study is to compare the outcome of OCT parameters for each group (Group A treated by intravitreal administered triamcinolone acetonide and Group B treated by intravitreal administered triamcinolone acetonide in combination with bevacizumab). Methods involved the selection of cases, dynamic measurements of the retina structures, so that, at the end, the data from the two groups of patients could be compared. The results showed a positive development in the short and medium term in both groups of patients.

Keywords: bevacizumab; clinically significant macular edema; optical coherence tomography; triamcinolone acetonide.

PubMed Disclaimer

References

    1. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative and angiogenic diseases. Prog Ret Eye Res. 2005;5:587–611. - PubMed
    1. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–927. - PubMed
    1. Duh E. Diabetic Retinopathy. Humana Press; 2008.
    1. Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A, Caulin C, Gaudric A, Bergmann JF. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45:3435–3441. - PubMed
    1. Bandello F, Pognuz DR, Pirracchio A, Polito A. Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2004;242:1024–1027. - PubMed

Publication types

MeSH terms

LinkOut - more resources